<code id='9946D92464'></code><style id='9946D92464'></style>
    • <acronym id='9946D92464'></acronym>
      <center id='9946D92464'><center id='9946D92464'><tfoot id='9946D92464'></tfoot></center><abbr id='9946D92464'><dir id='9946D92464'><tfoot id='9946D92464'></tfoot><noframes id='9946D92464'>

    • <optgroup id='9946D92464'><strike id='9946D92464'><sup id='9946D92464'></sup></strike><code id='9946D92464'></code></optgroup>
        1. <b id='9946D92464'><label id='9946D92464'><select id='9946D92464'><dt id='9946D92464'><span id='9946D92464'></span></dt></select></label></b><u id='9946D92464'></u>
          <i id='9946D92464'><strike id='9946D92464'><tt id='9946D92464'><pre id='9946D92464'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:leisure time    Page View:58779

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In